NRM on Vascular Perfusion in Healthy Adults

The Effect of Oral Nicotinamide Riboside on Systemic Vascular Perfusion in Healthy Adults: A Critical Foundation of Cerebrovascular Health, Cardiovascular Health, and Healthy Aging

Status

Enrolling by invitation

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06345443

Acronym

NRM

Enrollment

200

Registered

2024-04-03

Start date

2024-11-25

Completion date

2026-12-31

Last updated

2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Stiffness

Keywords

cardiovascular, Nicotinamide Riboside, Supplements, NRM

Brief summary

The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults.

Detailed description

This study is a randomized, double-blind, placebo-controlled, parallel-dose clinical trial. Participants will be randomly assigned to one of three groups. Study measurements will be completed at three timepoints and intervention taken daily throughout the subject's 12 weeks of participation.

Interventions

DIETARY_SUPPLEMENTNicotinamide Riboside Malate

Active supplement.

OTHERPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Masking description

The pharmacy will be responsible for randomization and dispensing appropriate randomized intervention.

Eligibility

Sex/Gender

ALL

Age

35 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* \>= 35 and \<=70 * Provides consent to participate in the study * Not pregnant at time of consent * Understands and agrees to follow all study procedures and limitations * Have no contraindicating comorbid health condition as determined by the clinical investigators

Exclusion criteria

* Pregnant, nursing, or trying to conceive * BMI Restrictions: \<35 * Allergy or sensitivity to study agent ingredients * Hypertension treated with medication * Use of natural health products containing nicotinamide riboside, quercetin, trans-resveratrol, or betaine anhydrous within 7 days prior to randomization and during the course of the study. * Surgery planned during the course of the trial * History or past diagnosis of chronic diseases, unstable medical conditions, blood/bleeding disorders or stroke * History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis. * Abnormal blood chemistries for renal or liver function (defined as 1 standard deviation outside of the normal range), alcohol dependence, uncontrolled thyroid disease, severe obesity (body mass index \>40 kg m-2), or weight stable for at least 3 months prior to enrolling in the study (defined as \>2 kg change in body mass). * An unstable medical or mental health condition as determined by the physician investigator.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants with Reduced Endothelial Stiffness	Baseline to End of study at 12 weeks	Endothelial Peripheral Arterial Tonometry testing will be used to assess endothelial stiffness changes over study

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRyan Hurt, MD, PhD

Mayo Clinic

PRINCIPAL_INVESTIGATORBrent Bauer, MD